Prestwood Karen M, Raisz Lawrence G
Division of Geriatrics, University of Connecticut Center on Aging, University of Connecticut Health Center, Farmington, Connecticut, USA.
Clin Cornerstone. 2002;4(6):31-41. doi: 10.1016/s1098-3597(02)90034-7.
Osteoporosis develops in older adults when the normal processes of bone formation and resorption become uncoupled or unbalanced, resulting in bone loss. Fractures are the result of decreased bone mass and strength and, in the case of wrist and hip fractures, usually involve a fall. Osteoporosis prevention and treatment programs should then focus on strategies that minimize bone resorption and maximize bone formation as well as on strategies that reduce falls. Optimal treatment and prevention of osteoporosis require modification of risk factors, particularly smoking cessation, adequate physical activity, and attention to diet, in addition to pharmacologic intervention. A number of pharmacologic options are now available to health care providers. This article focuses on US Food and Drug Administration-approved medications for osteoporosis and emphasizes the importance of using these agents as part of a comprehensive program that includes nonpharmacologic measures, complete diagnostic evaluation, and adequate follow-up with bone mineral density measurement.
当正常的骨形成和骨吸收过程出现脱节或失衡,导致骨质流失时,老年人就会患上骨质疏松症。骨折是骨量和骨强度下降的结果,就手腕和髋部骨折而言,通常是由跌倒所致。因此,骨质疏松症的预防和治疗方案应侧重于尽量减少骨吸收和最大化骨形成的策略,以及减少跌倒的策略。除了药物干预外,骨质疏松症的最佳治疗和预防还需要改变危险因素,特别是戒烟、进行适当的体育活动和注意饮食。现在医疗保健人员有多种药物选择。本文重点介绍美国食品药品监督管理局批准的治疗骨质疏松症的药物,并强调将这些药物作为综合方案的一部分使用的重要性,该方案包括非药物措施、完整的诊断评估以及通过骨密度测量进行充分的随访。